---
title: "阿斯利康、辉瑞、诺华…透视 MNC 2023 上半年公开的肿瘤领域专利"
date: 2023-08-04T23:01:33Z
draft: ["false"]
tags: [
  "fetched",
  "Insight数据库"
]
categories: ["Duty"]
---
阿斯利康、辉瑞、诺华…透视 MNC 2023 上半年公开的肿瘤领域专利 by Insight数据库
------
<div><section data-mpa-powered-by="yiban.io"><img data-backh="156" data-backw="562" data-ratio="0.2777777777777778" data-src="https://mmbiz.qpic.cn/sz_mmbiz_png/5dTQk9tMvZYF5Asn2uWS6ibKUibMjNE0VdQA1EQyZgTiahTWw3jjtRoiaBXefv90xXX0TfIyU2dNXmKDh7ubyX8n1Q/640?wx_fmt=png&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1" data-type="png" data-w="900" height="250px" width="900" src="https://mmbiz.qpic.cn/sz_mmbiz_png/5dTQk9tMvZYF5Asn2uWS6ibKUibMjNE0VdQA1EQyZgTiahTWw3jjtRoiaBXefv90xXX0TfIyU2dNXmKDh7ubyX8n1Q/640?wx_fmt=png&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1"></section><section><br></section><section><span>随着各大制药陆续披露各自 2023 上半年的业绩报告，肿瘤业务在其营收中的贡献也逐一浮出水面。</span></section><section><span><br></span></section><section><span>初步调研发现，<strong>辉瑞</strong>、<strong>阿斯利康</strong>、<strong>艾伯维</strong>、<strong>诺华</strong>与<strong>葛兰素史克（GSK）</strong>等公司上半年公开的肿瘤相关（分类号中含有 A61P35）PCT 专利在数量上均少于前期调研的罗氏公司</span><span>（详见往期文章&gt;&gt;&gt;</span><a target="_blank" href="http://mp.weixin.qq.com/s?__biz=MzA4MzkzMDYyNw==&amp;mid=2649893931&amp;idx=1&amp;sn=d688c270e9396d8438047daffdcfb20b&amp;chksm=87e87747b09ffe5177fcd148b9902e3eec9e667721b54b35893dbf4a060b4564e35686cb9e3a&amp;scene=21#wechat_redirect" textvalue="透视罗氏制药 2023 上半年公开的肿瘤领域专利" linktype="text" imgurl="" imgdata="null" data-itemshowtype="0" tab="innerlink" data-linktype="2"><span>透视罗氏制药 2023 上半年公开的肿瘤领域专利</span></a><span>）</span><span>，但<strong>在发明主题上却各有千秋。</strong></span></section><section><span><br></span></section><section><span>由于 PCT 途径是大部分申请人进行国际申请的首选途径，而且大部分 PCT 申请的公开日均早于其同族专利申请，<strong>故本文以</strong> <strong>2023 上半年公开的上述 MNC 申请的肿瘤相关 PCT 专利为线索，简要地分析各 MNC 最新的研发动态与方向。</strong></span></section><section><br></section><section><br></section><p><img data-backh="52" data-backw="562" data-galleryid="" data-ratio="0.09166666666666666" data-s="300,640" data-src="https://mmbiz.qpic.cn/mmbiz_png/5dTQk9tMvZZELxGdzcvb5smTN1Jpa5oSNVoeeMhPsWC6JvHGAhMNaWpTzd5Xup3rRSuibpcdEn0bBBx30uuEsKw/640?wx_fmt=png&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1" data-type="png" data-w="1080" src="https://mmbiz.qpic.cn/mmbiz_png/5dTQk9tMvZZELxGdzcvb5smTN1Jpa5oSNVoeeMhPsWC6JvHGAhMNaWpTzd5Xup3rRSuibpcdEn0bBBx30uuEsKw/640?wx_fmt=png&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1"></p><section><span><strong>小分子化合物</strong></span></section><section><span><br></span></section><section><span><span><strong><span> </span></strong></span><span><strong><span>  基础化合物专利</span></strong></span></span></section><section><br></section><section><span><em><span>写在前面：</span></em></span></section><section><br></section><section><span>本文所列的示例化合物结构中对于各专利大部分示例化合物所共有的部分以红色标识，共有部分中仍然可变的原子则以蓝色标识。</span></section><section><span><br></span></section><section><span><strong><span>1、选择性雄激素受体调控剂（SARMs）</span></strong></span></section><section><br></section><section><span>辉瑞申请的 WO2023275715 公开了作为 SARM 的化合物 1.1.1 的代谢产物，包括硫杂六氢嘧啶环的开环产物及 N-葡萄糖醋酸结合物、异喹啉环的氧化产物等，但通篇未披露所述代谢产物活性数据，而是对作为第二活性成分在于含有化合物 1.1.1 代谢产物的组合物中的 MC4R 拮抗剂披露了有关数据。</span></section><section><span><br></span></section><section><span>化合物 1.1.1</span></section><section><img data-galleryid="" data-ratio="0.9131455399061033" data-s="300,640" data-src="https://mmbiz.qpic.cn/sz_mmbiz_png/5dTQk9tMvZYAAuZL9vJpdYgsr9BVjxmuMVaz7tgzzibL9oMpmkEyFkPI8diaAChBp7RRzC2VJBDdaPF7lp7Lhw1g/640?wx_fmt=png" data-type="png" data-w="426" src="https://mmbiz.qpic.cn/sz_mmbiz_png/5dTQk9tMvZYAAuZL9vJpdYgsr9BVjxmuMVaz7tgzzibL9oMpmkEyFkPI8diaAChBp7RRzC2VJBDdaPF7lp7Lhw1g/640?wx_fmt=png"></section><section><br></section><section><strong><span><span>2、</span><span>黑素皮质素 4 受体（MC4R）拮抗剂</span></span></strong></section><section><span><br></span></section><section><span>辉瑞申请的 WO2023275715 所公开的以化合物 1.1.2 为代表的 3',4'-二氢-1'H-螺 [吡咯啉-3,2'-[1,8] 萘啶] 类化合物对 MC4R 的 Ki 最低可达 0.18nM。</span></section><section><br></section><section><span>化合物 1.1.2</span></section><section><img data-galleryid="" data-ratio="0.5613305613305614" data-s="300,640" data-src="https://mmbiz.qpic.cn/sz_mmbiz_png/5dTQk9tMvZYAAuZL9vJpdYgsr9BVjxmuiaEG4LmDamN4sibf6BvdBGEhRuzH7sBk8zexo2zVZKZVtU8IBcPfPUjw/640?wx_fmt=png" data-type="png" data-w="481" src="https://mmbiz.qpic.cn/sz_mmbiz_png/5dTQk9tMvZYAAuZL9vJpdYgsr9BVjxmuiaEG4LmDamN4sibf6BvdBGEhRuzH7sBk8zexo2zVZKZVtU8IBcPfPUjw/640?wx_fmt=png"></section><section><br></section><section><span><strong><span>3、HPK1 抑制剂</span></strong></span></section><section><span><strong><span><br></span></strong></span></section><section><span>阿斯利康公司申请的 WO2023001794A1 所公开的以化合物 1.1.3 为代表的 3-氨基吡嗪羧酰胺化合物对 HPK1 的 IC50 最低可 &lt;3nM。除了前述的母核，各示例化合物均在吡嗪环的 6 位带有咪唑稠合六元芳香环基取代。</span></section><section><span><br></span></section><section><span>化合物 1.1.3</span></section><section><img data-galleryid="" data-ratio="0.7075718015665796" data-s="300,640" data-src="https://mmbiz.qpic.cn/sz_mmbiz_png/5dTQk9tMvZYAAuZL9vJpdYgsr9BVjxmuQV51IR44HhxdhVGUI24ibtIXM4sN1eXQQLw3HWIcHnBmibjQlhiayYDXw/640?wx_fmt=png" data-type="png" data-w="383" src="https://mmbiz.qpic.cn/sz_mmbiz_png/5dTQk9tMvZYAAuZL9vJpdYgsr9BVjxmuQV51IR44HhxdhVGUI24ibtIXM4sN1eXQQLw3HWIcHnBmibjQlhiayYDXw/640?wx_fmt=png"></section><section><span><br></span></section><section><span><strong><span>4、PTPN2 降解剂</span></strong></span></section><section><br></section><section><span>WO2023019166（申请人：艾伯维）公开的以化合物 1.1.4 为代表的 PTPN2 降解剂对 PTPN2 的 DC50 最低可达 &lt;50nM。</span></section><section><span><br></span></section><section><span>化合物 1.1.4</span></section><section><img data-backh="497" data-backw="578" data-galleryid="" data-ratio="0.8590504451038575" data-s="300,640" data-src="https://mmbiz.qpic.cn/sz_mmbiz_png/5dTQk9tMvZYAAuZL9vJpdYgsr9BVjxmuyTxn5FmNgcYgMXGj2ZKWcgnrPsQIicDG11WyiarvpkiaRO7abnyMXQ1TQ/640?wx_fmt=png" data-type="png" data-w="674" src="https://mmbiz.qpic.cn/sz_mmbiz_png/5dTQk9tMvZYAAuZL9vJpdYgsr9BVjxmuyTxn5FmNgcYgMXGj2ZKWcgnrPsQIicDG11WyiarvpkiaRO7abnyMXQ1TQ/640?wx_fmt=png"></section><section><br></section><section><span><strong><span>5、TEAD 降解剂</span></strong></span></section><section><span><strong><span><br></span></strong></span></section><section><span>WO2023031801（申请人：诺华公司）公开的以化合物 1.1.5 为代表的 TEAD 降解剂对 TEAD1 的 DC50 最低可达 &lt;0.3nM。作为 YAP/YAZ-TEAD 蛋白-蛋白相互作用抑制剂的红色部分（可对照后文的化合物 1.2-2 与 1.2-3）还可以通过 * 标注的羧酰氨基或氧甲基与连接子相连。</span></section><section><span><br></span></section><section><span>化合物 1.1.5</span></section><section><img data-galleryid="" data-ratio="0.5170178282009724" data-s="300,640" data-src="https://mmbiz.qpic.cn/sz_mmbiz_png/5dTQk9tMvZYAAuZL9vJpdYgsr9BVjxmu0CG4v2ia7AoMJGtR22t2f18avELBPerpwyAW45ib1DpGnmmyRKWrViaVw/640?wx_fmt=png" data-type="png" data-w="617" src="https://mmbiz.qpic.cn/sz_mmbiz_png/5dTQk9tMvZYAAuZL9vJpdYgsr9BVjxmu0CG4v2ia7AoMJGtR22t2f18avELBPerpwyAW45ib1DpGnmmyRKWrViaVw/640?wx_fmt=png"></section><section><br></section><section><span><strong><span>6、PRMT5 抑制剂</span></strong></span></section><section><span><br></span></section><section><span>WO2023036974（申请人：阿斯利康）公开的一系列以化合物 1.1.6 为代表的 PRMT5 抑制剂对 PRMT5（+MTA）的 IC50 值可低达 nM 水平。</span></section><section><span><br></span></section><section><span>化合物 1.1.6</span></section><section><img data-galleryid="" data-ratio="0.9572446555819477" data-s="300,640" data-src="https://mmbiz.qpic.cn/sz_mmbiz_png/5dTQk9tMvZYAAuZL9vJpdYgsr9BVjxmutT6WzSOOoembsl1ocxhJXdEXy3AZ4SzO0zoNPOcCftJwFl7JibGOlkg/640?wx_fmt=png" data-type="png" data-w="421" src="https://mmbiz.qpic.cn/sz_mmbiz_png/5dTQk9tMvZYAAuZL9vJpdYgsr9BVjxmutT6WzSOOoembsl1ocxhJXdEXy3AZ4SzO0zoNPOcCftJwFl7JibGOlkg/640?wx_fmt=png"></section><section><br></section><section><span><strong><span>7、WRN 抑制剂</span></strong></span></section><section><br></section><section><span>GSK 与 Ideaya Biosciences Inc 联合申请的 WO2023062575 公开了以化合物 1.1.7 为代表的 WRN 抑制剂，其对 WRN 的 IC50 最低可 ≤ 100nM。</span></section><section><span><br></span></section><section><span>化合物 1.1.7</span></section><section><img data-galleryid="" data-ratio="0.4773060029282577" data-s="300,640" data-src="https://mmbiz.qpic.cn/sz_mmbiz_png/5dTQk9tMvZYAAuZL9vJpdYgsr9BVjxmu0LzOAbGN5QcvhN7pS7Gfocu2EBFKuSojic8Sn82ee2Bxib3spxxWDMgg/640?wx_fmt=png" data-type="png" data-w="683" src="https://mmbiz.qpic.cn/sz_mmbiz_png/5dTQk9tMvZYAAuZL9vJpdYgsr9BVjxmu0LzOAbGN5QcvhN7pS7Gfocu2EBFKuSojic8Sn82ee2Bxib3spxxWDMgg/640?wx_fmt=png"></section><section><br></section><section><span><strong><span>8、DNA 聚合酶 θ 抑制剂</span></strong></span></section><section><br></section><section><span>GSK 与 Ideaya Biosciences Inc 联合申请的 WO2023067515A1 公开的以化合物 1.1.8 为代表的噻二唑类化合物对 DNA 聚合酶 θ 的 IC50 最低可 ≤ 200nM。</span></section><section><span><br></span></section><section><span>化合物 1.1.8</span></section><section><img data-galleryid="" data-ratio="0.9032967032967033" data-s="300,640" data-src="https://mmbiz.qpic.cn/sz_mmbiz_png/5dTQk9tMvZYAAuZL9vJpdYgsr9BVjxmuWHckQe1Th9kh6cxB1aV0kXvz550zBjf77uGQPFfiajW5SoILCKJj4ZA/640?wx_fmt=png" data-type="png" data-w="455" src="https://mmbiz.qpic.cn/sz_mmbiz_png/5dTQk9tMvZYAAuZL9vJpdYgsr9BVjxmuWHckQe1Th9kh6cxB1aV0kXvz550zBjf77uGQPFfiajW5SoILCKJj4ZA/640?wx_fmt=png"></section><section><br></section><section><br></section><section><span><span><strong><span> </span></strong></span><span><strong><span>  外周专利</span></strong></span></span></section><section><span><strong><span><br></span></strong></span></section><section><img data-galleryid="" data-ratio="3.1657894736842107" data-s="300,640" data-src="https://mmbiz.qpic.cn/sz_mmbiz_png/5dTQk9tMvZYAAuZL9vJpdYgsr9BVjxmuMYoovDcNEJxqKM8ibKI8LTQ5l6IcvNgJYgqvwGuIYZcUiaIoevrVrwaQ/640?wx_fmt=png" data-type="png" data-w="760" src="https://mmbiz.qpic.cn/sz_mmbiz_png/5dTQk9tMvZYAAuZL9vJpdYgsr9BVjxmuMYoovDcNEJxqKM8ibKI8LTQ5l6IcvNgJYgqvwGuIYZcUiaIoevrVrwaQ/640?wx_fmt=png"></section><section><br></section><section><br></section><p><img data-backh="53" data-backw="578" data-galleryid="" data-ratio="0.09166666666666666" data-s="300,640" data-src="https://mmbiz.qpic.cn/mmbiz_png/5dTQk9tMvZZELxGdzcvb5smTN1Jpa5oSmkuYSKhxoZteNgXZAE0DDTL8Z3ibib4fSdyDObP4fGvLA9kFx8xacllw/640?wx_fmt=png" data-type="png" data-w="1080" src="https://mmbiz.qpic.cn/mmbiz_png/5dTQk9tMvZZELxGdzcvb5smTN1Jpa5oSmkuYSKhxoZteNgXZAE0DDTL8Z3ibib4fSdyDObP4fGvLA9kFx8xacllw/640?wx_fmt=png"></p><section><span><strong><span>生物大分子</span></strong></span></section><section><span><strong><span><br></span></strong></span></section><section><span><span><strong><span> </span></strong></span><span><strong><span>  基础专利</span></strong></span></span></section><section><span><br></span></section><section><img data-backh="241" data-backw="578" data-galleryid="" data-ratio="0.416" data-s="300,640" data-src="https://mmbiz.qpic.cn/sz_mmbiz_png/5dTQk9tMvZYAAuZL9vJpdYgsr9BVjxmutqMtqQgFJSiaGJzpQSMQLcYjYBRoCMd5sooDApL09xx9fXCmBCuRB2A/640?wx_fmt=png" data-type="png" data-w="625" src="https://mmbiz.qpic.cn/sz_mmbiz_png/5dTQk9tMvZYAAuZL9vJpdYgsr9BVjxmutqMtqQgFJSiaGJzpQSMQLcYjYBRoCMd5sooDApL09xx9fXCmBCuRB2A/640?wx_fmt=png"></section><section><br></section><section><span><span><strong><span> </span></strong></span><span><strong><span>  外周专利</span></strong></span></span></section><section><span><strong><span><br></span></strong></span></section><section><img data-backh="431" data-backw="578" data-galleryid="" data-ratio="0.7449306296691569" data-s="300,640" data-src="https://mmbiz.qpic.cn/sz_mmbiz_png/5dTQk9tMvZYAAuZL9vJpdYgsr9BVjxmudibKwDN3bGxvettBtTyPapPGEqTplxKXaIaXpFqNj8UibSmBiaLgbv65A/640?wx_fmt=png" data-type="png" data-w="937" src="https://mmbiz.qpic.cn/sz_mmbiz_png/5dTQk9tMvZYAAuZL9vJpdYgsr9BVjxmudibKwDN3bGxvettBtTyPapPGEqTplxKXaIaXpFqNj8UibSmBiaLgbv65A/640?wx_fmt=png"></section><section><br></section><section><br></section><section><br></section><p><img data-backh="53" data-backw="578" data-galleryid="" data-ratio="0.09166666666666666" data-s="300,640" data-src="https://mmbiz.qpic.cn/mmbiz_png/5dTQk9tMvZZELxGdzcvb5smTN1Jpa5oSgmzgu7wuUwYWH5bAUemnew7uoSV2mZ3rGslAnnpoyBGZySianhBRh6A/640?wx_fmt=png" data-type="png" data-w="1080" src="https://mmbiz.qpic.cn/mmbiz_png/5dTQk9tMvZZELxGdzcvb5smTN1Jpa5oSgmzgu7wuUwYWH5bAUemnew7uoSV2mZ3rGslAnnpoyBGZySianhBRh6A/640?wx_fmt=png"></p><section><span><strong><span>小  结</span></strong></span><br></section><section><span><br></span></section><section><span>本文提及的 MNC 及罗氏在 2023 年上半年公开的肿瘤相关 PCT 专利涉及的靶点如下表所示（排号内数值代表涉及的该公司申请的 PCT 专利数量）。</span></section><section><span><br></span></section><section><img data-backh="357" data-backw="578" data-galleryid="" data-ratio="0.6173421300659755" data-s="300,640" data-src="https://mmbiz.qpic.cn/sz_mmbiz_png/5dTQk9tMvZYAAuZL9vJpdYgsr9BVjxmu0gbLcbWU8xzK0wEXLdD5TVVkVF4CV23DFceJREficic6hlQ9TBRm9zRw/640?wx_fmt=png" data-type="png" data-w="1061" src="https://mmbiz.qpic.cn/sz_mmbiz_png/5dTQk9tMvZYAAuZL9vJpdYgsr9BVjxmu0gbLcbWU8xzK0wEXLdD5TVVkVF4CV23DFceJREficic6hlQ9TBRm9zRw/640?wx_fmt=png"></section><section><br></section><section><span>2023 上半年公开的上表中各 MNC 申请的肿瘤相关 PCT 专利涉及的靶点重叠率相对较低，其中<strong>涉及两家 MNC 申请的 PCT 专利中靶点则以加粗与下划线标示</strong>，提示各 MNC 肿瘤领域新药研发的差异化策略。</span></section><section><span><br></span></section><section><span>往期文章回顾 &gt;&gt; </span><span><a target="_blank" href="http://mp.weixin.qq.com/s?__biz=MzA4MzkzMDYyNw==&amp;mid=2649893931&amp;idx=1&amp;sn=d688c270e9396d8438047daffdcfb20b&amp;chksm=87e87747b09ffe5177fcd148b9902e3eec9e667721b54b35893dbf4a060b4564e35686cb9e3a&amp;scene=21#wechat_redirect" textvalue="透视罗氏制药 2023 上半年公开的肿瘤领域专利" linktype="text" imgurl="" imgdata="null" data-itemshowtype="0" tab="innerlink" data-linktype="2">透视罗氏制药 2023 上半年公开的肿瘤领域专利</a></span><span><br></span></section><section><span></span></section><section><br></section><section data-mpa-template="t" mpa-from-tpl="t"><section data-mpa-template="t" mpa-from-tpl="t"><section mpa-from-tpl="t"><section mpa-from-tpl="t"><section mpa-from-tpl="t"><section><section><span><strong>封面来源：</strong></span><span>站酷海洛 Plus</span></section><section><span><strong>免责声明：</strong><span>本文仅作信息分享，不代表 Insight 立场和观点，也不作治疗方案推荐和介绍。如有需求，请咨询和联系正规医疗机构。</span></span></section><section><br></section><section><span><strong>编辑</strong>：Hebe</span></section><section><span><strong><span>PR 稿对接</span></strong><span>：微信 insightxb</span></span></section><section><span><strong><span>投稿</span></strong><span>：微信 insightxb；邮箱 insight@dxy.cn</span></span></section><section><span><br></span></section><hr><section><br></section><section><span>点击卡片进入 </span><span><strong>Insight 小程序</strong></span></section><section><span>国内审评进度、全球新药开发…</span></section><section><span>随时随地查！</span></section><section><mp-common-miniprogram data-miniprogram-nickname="Insight医药情报助手" data-miniprogram-avatar="http://mmbiz.qpic.cn/mmbiz_png/8T4HVUJDuYF2WXbXCEqZl90lJ8NIuiby0SqbBwkibzz6nglM7ia9fJMkn1G6Chz8bVK0yE3jicBBrLFgIOSibcsgk3w/640?wx_fmt=png&amp;amp;wxfrom=200" data-miniprogram-title="点击卡片，医药数据一键查询！" data-miniprogram-imageurl="http://mmbiz.qpic.cn/sz_mmbiz_jpg/5dTQk9tMvZYRT3iaiao5IpcwWsK7fibuaxPgkckAWgsCTDgFiaYC40enddrMSOMbhrtGrbx0epaHIRan3MVfCHgI8g/0?wx_fmt=jpeg" data-miniprogram-type="card" data-miniprogram-servicetype="0" data-pluginname="insertminiprogram" data-miniprogram-appid="wx33d4c3735820a33e" data-weui-theme="light" data-miniprogram-path="pages/index/index?dxa_adplatform=7db80b691672736549"></mp-common-miniprogram></section><section><img data-backh="35" data-backw="542" data-before-oversubscription-url="https://mmbiz.qpic.cn/mmbiz_png/5dTQk9tMvZYnVllCouEEOdqo2iaqqnfQKB92kyKXnTAsX7DloH6icYmFC8LN4mwrwZXeQ5pqqwkDc38ib16FbGZpA/640?wx_fmt=png" data-copyright="0" data-ratio="0.06388888888888888" data-s="300,640" data-src="https://mmbiz.qpic.cn/mmbiz_png/5dTQk9tMvZYnVllCouEEOdqo2iaqqnfQKB92kyKXnTAsX7DloH6icYmFC8LN4mwrwZXeQ5pqqwkDc38ib16FbGZpA/640?wx_fmt=png&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1" data-type="png" data-w="1080" src="https://mmbiz.qpic.cn/mmbiz_png/5dTQk9tMvZYnVllCouEEOdqo2iaqqnfQKB92kyKXnTAsX7DloH6icYmFC8LN4mwrwZXeQ5pqqwkDc38ib16FbGZpA/640?wx_fmt=png&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1"></section><section><span>多样化功能、可溯源数据……</span></section><section><span>Insight 数据库网页版等你体验<img data-ratio="1" data-src="https://mmbiz.qpic.cn/sz_mmbiz_png/5dTQk9tMvZapSKkMo4zKejyF1kwocYAdDgiaHuOPBnUFhqWicIL2pJVarklchCnjDxBbdCLIt3FXvuGicJOXnON7A/640?wx_fmt=png&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1" data-type="png" data-w="64" src="https://mmbiz.qpic.cn/sz_mmbiz_png/5dTQk9tMvZapSKkMo4zKejyF1kwocYAdDgiaHuOPBnUFhqWicIL2pJVarklchCnjDxBbdCLIt3FXvuGicJOXnON7A/640?wx_fmt=png&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1"></span><br></section><section><span>点击阅读原文，<strong>立刻</strong><strong>解锁</strong>！</span><img data-copyright="0" data-ratio="0.125" data-s="300,640" data-src="https://mmbiz.qpic.cn/mmbiz_png/5dTQk9tMvZZsSTG4CvxVOsgyYs36Biav0Peywg39IiboTfliboldm2SDTmYnbfopNhFNPQ8XXlfF9GeoNAGLRM3KQ/640?wx_fmt=png&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1" data-type="png" data-w="1080" src="https://mmbiz.qpic.cn/mmbiz_png/5dTQk9tMvZZsSTG4CvxVOsgyYs36Biav0Peywg39IiboTfliboldm2SDTmYnbfopNhFNPQ8XXlfF9GeoNAGLRM3KQ/640?wx_fmt=png&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1"></section></section></section></section></section></section></section><section><section><br></section></section><section><section><br></section></section><p><mp-style-type data-value="3"></mp-style-type></p></div>  
<hr>
<a href="https://mp.weixin.qq.com/s/-eTloxwRtOurGeY4S-saVw",target="_blank" rel="noopener noreferrer">原文链接</a>
